glimepiride has been researched along with Weight Gain in 16 studies
glimepiride: structure given in first source
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 9.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes." | 9.17 | Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. ( Bader, G; Geransar, P; Schweizer, A, 2013) |
| "Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain." | 9.14 | Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010) |
| "Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2 diabetes inadequately controlled with metformin." | 6.78 | Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years. ( Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ, 2013) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 5.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes." | 5.17 | Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. ( Bader, G; Geransar, P; Schweizer, A, 2013) |
| "As weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors." | 5.14 | Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. ( Blonde, L; Bode, BW; Garber, A; Hale, PM; Hammer, M; Magwire, M; Testa, MA, 2010) |
| "Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain." | 5.14 | Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010) |
| "Glimepiride reduced A1C similarly to metformin with greater weight gain, and there was comparable safety over 24 weeks in the treatment of pediatric subjects with type 2 diabetes." | 5.12 | Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. ( Cara, JF; Danne, T; Gottschalk, M; Vlajnic, A, 2007) |
| "The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes." | 5.10 | Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. ( Fritsche, A; Häring, HU; Schweitzer, MA, 2003) |
| "Seventy drug-naïve patients with type 2 diabetes (mean age, 52." | 3.30 | Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023) |
| "Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2 diabetes inadequately controlled with metformin." | 2.78 | Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years. ( Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ, 2013) |
" Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (| 2.73 | Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. ( Busch, K; Janka, HU; Plewe, G, 2007) | |
| " Insulin dosage was titrated to target FBG | 2.71 | Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. ( Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H, 2005) |
| "Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin." | 2.48 | Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. ( Basit, A; Fawwad, A; Riaz, M, 2012) |
| "Patients with type 2 diabetes who are failing on oral agents will generally gain a large amount of body fat when switched to insulin treatment." | 1.32 | Prevention of weight gain in type 2 diabetes requiring insulin treatment. ( de Boer, H; Jansen, M; Koerts, J; Verschoor, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, S | 1 |
| Sohn, M | 1 |
| Florez, JC | 1 |
| Nauck, MA | 1 |
| Ahn, J | 1 |
| Gu, T | 1 |
| Ma, J | 2 |
| Zhang, Q | 1 |
| Zhu, L | 1 |
| Zhang, H | 1 |
| Xu, L | 1 |
| Cheng, J | 1 |
| Shi, B | 1 |
| Li, D | 1 |
| Shao, J | 1 |
| Sun, Z | 1 |
| Zhong, S | 1 |
| Bi, Y | 1 |
| Zhu, D | 1 |
| Gallwitz, B | 1 |
| Rosenstock, J | 1 |
| Emser, A | 1 |
| von Eynatten, M | 1 |
| Woerle, HJ | 1 |
| Bader, G | 1 |
| Geransar, P | 1 |
| Schweizer, A | 1 |
| Yang, W | 1 |
| Xing, X | 1 |
| Lv, X | 1 |
| Li, Y | 1 |
| Yuan, G | 1 |
| Sun, F | 1 |
| Wang, W | 1 |
| Woloschak, M | 1 |
| Lukashevich, V | 1 |
| Kozlovski, P | 1 |
| Kothny, W | 1 |
| Derosa, G | 1 |
| Bonaventura, A | 1 |
| Bianchi, L | 1 |
| Romano, D | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Bode, BW | 1 |
| Testa, MA | 1 |
| Magwire, M | 1 |
| Hale, PM | 1 |
| Hammer, M | 1 |
| Blonde, L | 1 |
| Garber, A | 1 |
| Matthews, DR | 1 |
| Dejager, S | 1 |
| Ahren, B | 1 |
| Fonseca, V | 1 |
| Ferrannini, E | 1 |
| Couturier, A | 1 |
| Foley, JE | 1 |
| Zinman, B | 1 |
| Basit, A | 1 |
| Riaz, M | 1 |
| Fawwad, A | 1 |
| Fritsche, A | 1 |
| Schweitzer, MA | 2 |
| Häring, HU | 1 |
| de Boer, H | 2 |
| Jansen, M | 2 |
| Koerts, J | 1 |
| Verschoor, L | 2 |
| Janka, HU | 2 |
| Plewe, G | 2 |
| Riddle, MC | 1 |
| Kliebe-Frisch, C | 1 |
| Yki-Järvinen, H | 1 |
| Keizers, R | 1 |
| Ruineman-Koerts, J | 1 |
| Green, JB | 1 |
| Feinglos, MN | 1 |
| Busch, K | 1 |
| Gottschalk, M | 1 |
| Danne, T | 1 |
| Vlajnic, A | 1 |
| Cara, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial[NCT02280486] | Phase 4 | 388 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metfo[NCT00622284] | Phase 3 | 1,560 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Mono[NCT01357252] | Phase 3 | 279 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes[NCT00294723] | Phase 3 | 746 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power) | ||
| Basal Insulin Therapy in Patients With Insulin Resistance: A 6 Month Comparison of Insulin Glargine and NPH Insulin[NCT01854723] | Phase 4 | 0 participants (Actual) | Interventional | 2013-04-30 | Withdrawn | ||
| Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial[NCT00641407] | Phase 4 | 100 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment[NCT00151697] | Phase 3 | 150 participants (Anticipated) | Interventional | 2005-05-31 | Completed | ||
| Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus[NCT00736515] | Phase 4 | 160 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study[NCT00353691] | Phase 3 | 100 participants | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | -28.47 |
| Glimepiride | -18.72 |
This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 104
| Intervention | kg (Mean) |
|---|---|
| Linagliptin | -1.39 |
| Glimepiride | 1.29 |
This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 52
| Intervention | kg (Mean) |
|---|---|
| Linagliptin | -1.12 |
| Glimepiride | 1.38 |
(NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | 0 |
| Glimepiride | 1 |
(NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dl (Mean) |
|---|---|
| Linagliptin | 1 |
| Glimepiride | 0 |
(NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | 1 |
| Glimepiride | 3 |
(NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | -11 |
| Glimepiride | -7 |
This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | -2.34 |
| Glimepiride | -8.72 |
This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Linagliptin | -8.40 |
| Glimepiride | -15.24 |
The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule. (NCT00622284)
Timeframe: Baseline and week 104
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.21 |
| Glimepiride | -0.41 |
(NCT00622284)
Timeframe: Baseline and week 12
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.43 |
| Glimepiride | -0.75 |
(NCT00622284)
Timeframe: Baseline and week 16
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.45 |
| Glimepiride | -0.78 |
(NCT00622284)
Timeframe: Baseline and week 28
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.43 |
| Glimepiride | -0.74 |
Difference of base percent value [Week x(%) - baseline (%)] (NCT00622284)
Timeframe: Baseline and week 4
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.26 |
| Glimepiride | -0.33 |
(NCT00622284)
Timeframe: Baseline and week 40
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.42 |
| Glimepiride | -0.69 |
(NCT00622284)
Timeframe: Baseline and week 52
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.41 |
| Glimepiride | -0.63 |
(NCT00622284)
Timeframe: Baseline and week 65
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.32 |
| Glimepiride | -0.53 |
(NCT00622284)
Timeframe: Baseline and week 78
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.22 |
| Glimepiride | -0.43 |
(NCT00622284)
Timeframe: Baseline and week 8
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.37 |
| Glimepiride | -0.58 |
(NCT00622284)
Timeframe: Baseline and week 91
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.21 |
| Glimepiride | -0.43 |
This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.16 |
| Glimepiride | -0.36 |
This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52
| Intervention | Percent (Mean) |
|---|---|
| Linagliptin | -0.36 |
| Glimepiride | -0.57 |
A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 104
| Intervention | Patients (Number) |
|---|---|
| Linagliptin | 58 |
| Glimepiride | 280 |
A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 52
| Intervention | Patients (Number) |
|---|---|
| Linagliptin | 41 |
| Glimepiride | 249 |
The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104
| Intervention | Percentage of patients (Number) |
|---|---|
| Linagliptin | 10.9 |
| Glimepiride | 14.7 |
The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Linagliptin | 16.9 |
| Glimepiride | 22.7 |
The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104
| Intervention | Percentage of patients (Number) |
|---|---|
| Linagliptin | 21.0 |
| Glimepiride | 28.3 |
The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Linagliptin | 29.6 |
| Glimepiride | 38.9 |
Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104 (NCT00622284)
Timeframe: Week 104
| Intervention | Percentage of patients (Number) |
|---|---|
| Linagliptin | 26.2 |
| Glimepiride | 33.5 |
Change in body weight from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.70 |
| Lira 1.2 | -1.89 |
| Glimepiride | 0.95 |
Change in body weight from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.43 |
| Lira 1.2 | -1.68 |
| Glimepiride | 1.05 |
Change in body weight from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.45 |
| Lira 1.2 | -2.05 |
| Glimepiride | 1.12 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -15.82 |
| Lira 1.2 | -9.36 |
| Glimepiride | 1.97 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -12.06 |
| Lira 1.2 | -5.45 |
| Glimepiride | 4.57 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -25.57 |
| Lira 1.2 | -15.21 |
| Glimepiride | -5.29 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -0.88 |
| Lira 1.2 | -0.59 |
| Glimepiride | -0.28 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -0.71 |
| Lira 1.2 | -0.44 |
| Glimepiride | -0.16 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -1.14 |
| Lira 1.2 | -0.84 |
| Glimepiride | -0.51 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -37.15 |
| Lira 1.2 | -27.34 |
| Glimepiride | -24.85 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 156 weeks. The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -34.83 |
| Lira 1.2 | -25.68 |
| Glimepiride | -23.84 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -37.4 |
| Lira 1.2 | -30.8 |
| Glimepiride | -24.5 |
Change in mean prandial increments of plasma glucose from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -11.76 |
| Lira 1.2 | -8.28 |
| Glimepiride | -7.95 |
Change in mean prandial increments (incr.) of plasma glucose from baseline (week 0) to 156 weeks. The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -11.01 |
| Lira 1.2 | -7.53 |
| Glimepiride | -7.97 |
Change in mean prandial increments of plasma glucose from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -9.6 |
| Lira 1.2 | -8.4 |
| Glimepiride | -5.6 |
Total number of hypoglycaemic episodes occuring from baseline (week 0) to 104 weeks (end of the 52-week extension). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 0-104
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Glimepiride | 0 | 533 | 405 |
| Lira 1.2 | 0 | 68 | 133 |
| Lira 1.8 | 1 | 71 | 87 |
Total number of hypoglycaemic episodes occuring from week 104 to end of trial (week 195). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 104-195
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Glimepiride | 1 | 34 | 4 |
| Lira 1.2 | 0 | 3 | 1 |
| Lira 1.8 | 0 | 13 | 3 |
2 reviews available for glimepiride and Weight Gain
| Article | Year |
|---|---|
Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medi | 2012 |
Are sulfonylureas passé?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Weight Gain | 2006 |
13 trials available for glimepiride and Weight Gain
| Article | Year |
|---|---|
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Gl | 2023 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; | 2019 |
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; | 2013 |
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metf | 2013 |
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China; | 2015 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2010 |
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog | 2003 |
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog | 2003 |
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog | 2003 |
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog | 2003 |
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hy | 2005 |
Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; F | 2006 |
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2007 |
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.
Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; | 2007 |
1 other study available for glimepiride and Weight Gain
| Article | Year |
|---|---|
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com | 2004 |